10-K: BioAdaptives Files Annual Report, Focuses on Product Reformulation

BioAdaptives, Inc. files its annual 10-K report for the fiscal year ended December 31, 2025, detailing business operations, financial condition, and future outlook.

Summary

• BioAdaptives, Inc. has filed its annual 10-K report for the fiscal year ending December 31, 2025.
• The company is focused on investigating, marketing, and distributing natural plant, algal, and cyanobacteria-based products and medical devices.
• Key product areas include nootropics, anti-aging, weight control, relaxation, pain relief, and anti-viral benefits.
• BioAdaptives is reformulating its product line and plans to launch new products starting in Q2 2025.
• The company acquired the rights to the Lung Flute medical device in April 2024 and plans to expand its sales efforts.
• New product developments include MyndMed for cognitive enhancement, Zeranovia for weight loss, and PawPaRegen for pet wellness.
• The company reported minimal revenues of $18,278 for 2025 and $12,669 for 2024.
• Operating expenses for 2025 were $1,054,688, primarily funded through shareholder investments and loans.
• The company faces substantial doubt about its ability to continue as a going concern due to accumulated deficits and reliance on external financing.
• The company's common stock is traded on the OTC Pink Sheets, characterized by limited and sporadic trading activity.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as having a very negative sentiment due to the company's minimal revenues, significant accumulated deficit, auditor's going concern warning, and the challenges associated with its penny stock status.

Positives

• The company is actively reformulating its product line and launching new products, indicating a focus on innovation and market adaptation.
• Expansion plans for the Lung Flute medical device target broader markets including medical communities, pharmacies, gyms, and senior communities.
• Development of new products like MyndMed (cognitive enhancement), Zeranovia (weight loss), and PawPaRegen (pet wellness) addresses diverse health and wellness needs.
• Zeranovia shows promising results in clinical trials, with participants losing 5-11 pounds in 7-10 days, and is designed to complement GLP-1/GIP treatments.
• The company has a robust direct-to-consumer (DTC) digital marketing strategy and is exploring partnerships within the telehealth industry.
• The company has secured new investment partners for its Series D preferred shares.
• The company's common stock has seen some price appreciation during 2025, reaching a high of $0.0999 in Q1.

Negatives

• The company reported very low revenues of $18,278 for 2025 and $12,669 for 2024.
• Significant operating expenses of $1,054,688 in 2025, largely funded by external financing, leading to an accumulated deficit of $10,721,204.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to its financial condition and reliance on future financing.
• The company's common stock is a penny stock, subject to restrictive SEC regulations that may limit trading activity and investor interest.
• The market for BioAdaptives shares is extremely limited and sporadic, with wide fluctuations in trading prices.
• The company has no cash flows to support operations and relies on external sources, making future financing uncertain.
• The company has a limited operating history and has been unsuccessful with previous business plans.
• The company has not paid cash dividends and does not expect to in the foreseeable future.

Risks

• Limited operating history and past unsuccessful business plans.
• Reliance on external financing sources, which are subject to market and regulatory risks.
• Uncertainty in the ability to raise adequate capital in the equity securities market.
• The company's new products are still in the development stage and not expected to be on the market until Q1 or Q2 2025.
• Potential shortfall of funding due to uncertainty in raising capital.
• The capital-intensive nature of the business and the need for continuous expenditures on R&D and marketing.
• Loss of key individuals could have an adverse effect on the company.
• Inability to attract and retain qualified personnel and consultants.
• Challenges in managing expanding operations and potential strain on managerial, operational, and financial resources.
• Changes in governmental regulation affecting food products and nutritional supplements.
• Uninsured operating risks such as equipment breakdown, labor disputes, supply chain failures, product contamination, and acts of God.
• Significant competition from better-capitalized companies in the nutraceutical industry.
• Inadequate internal controls could lead to unreliable financial reporting and misinformation.
• The costs of being a public company could result in the inability to continue as a going concern.
• Indemnification of directors and officers may result in significant costs and hurt stockholder interests.
• The limited and sporadic market for the company's shares may impact its ability to obtain financing.
• Penny stock regulations may limit a stockholder's ability to buy and sell common stock.
• The market for penny stocks has experienced fraud and abuse, which could adversely impact the company's stock.
• The Board of Directors has the authority to issue preferred stock with terms that may not be beneficial to common stockholders.
• Future sales of common stock could adversely affect the market price.
• Conversions of preferred stock to common stock and resales could adversely affect the market price.
• Lack of independent audit, nominating, or compensation committees limits stockholder protections against interested-director transactions and conflicts of interest.

Future Outlook

The company plans to continue research and investigation activities to identify new products or markets and improve existing products and marketing. They also intend to seek strategic or complementary acquisitions. The company anticipates that future expenditure levels will remain relatively consistent until the business plan is fully implemented, after which expenses and working capital requirements may increase significantly. The company expects to issue additional shares of common stock for cash and services within the next 12 months to mitigate going concern risks.

Management Comments

• "Our new products are very good and for a variety of reasons, including because we outsource our manufacturing, we are sufficiently nimble to increase production and sales if and when demand requires."
• "It is the belief of management that our current finance partners, shareholders and the proceeds from our sales of Preferred D will be able provide sufficient working capital necessary to support and preserve the integrity of the corporate entity."
• "The Company does not expect to generate any meaningful revenue or incur operating expenses for purposes other than fulfilling the obligations of a reporting company under the Exchange Act unless and until such time that the Company begins meaningful operations."
• "The Company believes that its expectations as to its ability to secure additional capital are reasonable, but there is no guarantee that the Company will receive sufficient funding to sustain operations or implement any future business plan steps."

Industry Context

StockSavvy.ai notes that BioAdaptives operates in the highly competitive health and wellness sector, focusing on natural supplements and medical devices. The company's strategy of reformulating products and developing new ones like MyndMed and Zeranovia aligns with market trends towards cognitive enhancement and weight management solutions. The mention of Zeranovia complementing GLP-1 treatments indicates an awareness of emerging pharmaceutical trends in weight loss.

Comparison to Industry Standards

• The company's reported revenues of $18,278 for 2025 are significantly below industry averages for established nutraceutical companies, highlighting its early-stage or struggling financial position.
• The substantial accumulated deficit of over $10.7 million and the auditor's "substantial doubt" about the company's ability to continue as a going concern are critical indicators of financial distress, contrasting sharply with financially stable industry players.
• The reliance on external financing and the limited market for its penny stock place BioAdaptives at a disadvantage compared to larger, publicly traded competitors on major exchanges with easier access to capital.
• While specific competitors are not named, the general market for nootropics, anti-aging, and weight loss supplements is crowded with both established brands and emerging startups, making market penetration and growth a significant challenge.

Management Changes

Corporate Governance

Legal Proceedings

• The Company is not a party to any pending legal proceedings, and no such proceedings are known to be contemplated.

Related Party Transactions

• During the year ended December 31, 2024, accounts payable of $2,729 was paid by a related party and due to related party of $5,106 was forgiven.
• As of December 31, 2025 and 2024, the Company owed Dr. Edward E. Jacobs, M.D., $0.
• In May 2024, the Company entered into an employment agreement with James E. Keener as CEO, with a salary of $300,000 per annum, payable in cash or stock. In 2025 and 2024, $300,000 and $158,871 were recorded for payroll, with Series D Preferred Stock issued for compensation.
• In May 2024, the Company entered into an employment agreement with a director (Gimhana Dissanayake) with a salary of $5,000 per month. In 2025 and 2024, $60,000 and $50,000 were recorded for payroll, with Series D Preferred Stock issued for compensation.
• In January 2025, the Company entered into an employment agreement with a director (Mary Wikins) with a salary of $5,000 per month. In 2025, $55,000 was recorded for payroll, with Series D Preferred Stock issued for compensation.
• During the year ended December 31, 2024, the Company issued notes payable to a related party of $32,096.
• During the year ended December 31, 2024, notes payable to a related party of $4,283 and accrued interest of $856 were forgiven.

Stakeholder Impact

• Shareholders: The company's penny stock status, limited trading, and significant financial challenges (going concern doubt, accumulated deficit) pose substantial risks to shareholder value. Future stock issuances and preferred stock conversions could dilute existing shareholder equity.
• Employees: The company currently has only one full-time executive employee. The reliance on consultants and hourly labor suggests limited direct employee impact, but the company's financial instability could affect future employment opportunities.
• Creditors: The company's ability to meet its obligations is uncertain, as indicated by the going concern warning. Convertible notes and derivative liabilities represent potential future claims on assets.
• Suppliers: The company outsources manufacturing and relies on suppliers for raw materials, some of which are imported from China, creating potential risks related to supply chain disruptions and pricing increases.

Next Steps

• Reformulate entire product line and launch new products starting from Q2 2025.
• Expand sales efforts for the Lung Flute device to target medical communities, pharmacies, gyms, athletic clubs, and senior communities.
• Explore agreements with other medical device manufacturers and intellectual property owners.
• Complete pre-launch phase for MyndMed.
• Complete clinical trial for Zeranovia for launch in the last quarter of 2025.
• Launch Canine Product PawPaRegen.
• Continue research and investigation activities to identify new products or markets and improve existing products and marketing.
• Seek strategic or complimentary acquisitions.
• Issue additional shares of common stock for cash and services during the next 12 months.

Key Dates

Recommendation

The company is in a highly speculative, early-stage phase with significant financial challenges, including a going concern warning and minimal revenue. While new product development and market expansion plans are positive, the substantial risks and uncertainties associated with its financial health and penny stock status warrant a cautious 'hold' recommendation. Investors should monitor future financing efforts and product launch success closely.

Keywords

BioAdaptives, 10-K, Annual Report, Nutraceuticals, Dietary Supplements, Medical Devices, Cognitive Health, Weight Loss, Anti-aging, Pet Wellness, SEC Filing, Financial Statements, Going Concern